Clinical Trial to Assess the Efficacy and Safety of EASYDEW MD REGEN Cream Containing Neopop-S.

NCT05982509 | Completed

• 1 other identifier: G2204
• Study Type: interventional
• Target: 20
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this clinical study is to evaluate the effect on skin regeneration after applying EasyDew MD Regen Cream containing Neopep-S, a regeneration factor, to patients who have undergone picosure picosure laser skin treatment as needed.

Conditions

Laser-Induced Scar

Outcome Measures

Primary Outcomes (1)

• Transepidermal water loss Transcutaneous water loss (TEWL) measured

  Before, immediately after treatment, and one month after application of the medical device Transcutaneous water loss (TEWL) measured

  Before, immediately after treatment, and one month after application

Study Arms (2)

No intervention

NO INTERVENTION

Control group: 10 people without treatment

Treatment

EXPERIMENTAL

Study Group: 10 People Applying EasyDew Regen MD Cream

Device: EasyDew Regen MD Cream

Interventions

EasyDew Regen MD Cream DEVICE

For the study group, I received the prescription Easy Dew Regen MD Cream from Picosure Laser Apply an appropriate amount twice a day (morning and evening) to the skin of the area so that it can be absorbed well do. The control group is the non-chalant group. However, for one month after the procedure, it is not a medical device The normal moisturizer you use at home is available, and the area where you have undergone laser treatment Apply it twice a day (morning and evening) to the skin so that it can be absorbed well.

Treatment

Eligibility Criteria

• Age: 19 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Those aged 19 to 65 who have undergone picosure laser treatment on facial and body skin tissues
• Decided to participate in this clinical study and signed a written informed consent the subject

You may not qualify if:

• Subjects with uncontrolled diabetes
• Subjects with uncontrolled hypertension and cardiovascular disease
• Subjects with hemorrhagic diseases such as hemophilia
• Immunosuppressants, corticosteroids, cytotoxic agents, and anticoagulants can affect the results Subjects who are or are scheduled to receive medication for an extended period of time
• Acute or chronic skin disease causes stage progression or active bacteria in the application area Who has a virus infection
• When the researcher's judgment determines that participation in the study is inappropriate (e.g. keloid constitution)

Sponsors & Collaborators

• Eun-ji Kim: lead

Study Sites (1)

Ajou University Hospital

Gyeonggi-do, South Korea

Location

Related Publications (1)

• Kim YH, Lee SJ, Kim HS, Woo SS, Kim MJ, Lim H, Lee IJ, Park YJ. Attenuation of Subclinical TNF-alpha Signalling in Xerotic Skin by AIMP-1 Derived Peptide Containing Moisturiser Leads to Skin Barrier Recovery. Exp Dermatol. 2025 Dec;34(12):e70183. doi: 10.1111/exd.70183.

  PMID: 41355341 DERIVED

Study Officials

• Jihye Lee

  CGBio Inc.

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: SUPPORTIVE CARE
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Clinical Trial Manager

Study Record Dates

• First Submitted: July 28, 2023
• First Posted: August 8, 2023
• Study Start: November 11, 2022
• Primary Completion: July 27, 2023
• Study Completion: July 27, 2023
• Last Updated: August 8, 2023

Record last verified: 2023-08

Data Sharing

• IPD Sharing: Will not share

Locations

KR (1)